Login
Edesa Biotech, Inc. logo

Edesa Biotech, Inc.

edesabiotech.com

What Do They Do?

Develops drug candidates for patients with inflammatory and immune-related diseases, including vitiligo, allergic contact dermatitis and acute respiratory distress syndrome.

Who Are Their Customers?

The company has no customers for its investigational medicines. If a candidate is approved, it plans to sell through its own sales force or use outside sales and marketing, licensing, collaboration or distribution partners.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Jun 30, 2026
Net income
▼ −209% (Loss)
vs −$1.7M in Q3 FY2025
  • Nov 8, 2026 Licensed paridiprubart development and sales rights in Japan to Kyorin Kyorin will handle development and commercialization in Japan; the company retains rights elsewhere and will manufacture and supply the licensed products.

Program focus The latest report describes a pulmonary fibrosis program under evaluation; the older report described development for systemic sclerosis.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support